STOK Insider Trading Activity and SEC Form 4 Filings
STOK insider trading summary
Over the past 12 months, insiders at Stoke Therapeutics, Inc. (STOK) reported 60 sales worth $8.0M by 6 insiders and no open-market purchases on SEC Form 4. Net insider selling was $8.0M.
Latest STOK insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 2, 2026 | Barry Ticho | Chief Medical Officer | Sell | $185K (6,995 @ $26.38) |
| Nov 2, 2026 | Barry Ticho | Chief Medical Officer | Sell | $5K (200 @ $26.99) |
| Oct 2, 2026 | Jonathan Allan | General Counsel & Corp Sec | Sell | $17K (627 @ $26.33) |
| Oct 1, 2026 | Barry Ticho | Chief Medical Officer | Sell | $27K (1,051 @ $26.16) |
| Sep 1, 2026 | Barry Ticho | Chief Medical Officer | Sell | $120K (3,945 @ $30.51) |
| Sep 1, 2026 | Barry Ticho | Chief Medical Officer | Sell | $50K (1,600 @ $31.06) |
| Aug 18, 2026 | Jonathan Allan | General Counsel & Corp Sec | Sell | $5K (145 @ $32.47) |
| Aug 18, 2026 | Edward M. MD Kaye | Insider | Sell | $382K (11,930 @ $32.01) |
| Aug 18, 2026 | Barry Ticho | Chief Medical Officer | Sell | $8K (242 @ $32.47) |
| Aug 18, 2026 | Jonathan Allan | General Counsel & Corp Sec | Sell | $87K (2,716 @ $32.01) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.